This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Daqing Li, MD; Elizabeth Shugert, MD; Ming Guo, PhD; Jeffrey S. Bishop, MS; Bert W. O'Malley, Jr, MD

Arch Otolaryngol Head Neck Surg. 2001;127:1319-1324.

Objective  To determine the feasibility and efficacy of combination nonviral lipid-formulated murine interleukin 2 (mIL-2) and polymer-formulated murine interleukin 12 (mIL-12) gene therapy for head and neck squamous cell carcinoma (HNSCC) in a murine model.

Methods  Randomized, controlled studies in a murine HNSCC model. Tumors were established in the floor of mouth in C3H/HeJ immunocompetent mice. Established tumors were directly injected with lipid-formulated mIL-2 and polymer-formulated mIL-12 alone and in combination. Antitumor responses, cytokine expression, and natural killer cell and cytolytic T-lymphocyte activity were assayed.

Results  The use of combined mIL-2 and mIL-12 gene therapy resulted in significant antitumor effects, compared with each of the single-cytokine and no-treatment (control) groups (P = .01 to P = .02). Tumors treated with the formulated cytokine genes showed an increased level of the corresponding proteins and decreased level of transforming growth factor ß (TGF-ß) expression. Combined mIL-2 and mIL-12 treatment consistently produced the greater activation of cytolytic T-lymphocyte and natural killer cells than did single-cytokine treatment or other controls at all concentrations tested. Augmented immune responses correlated with clinical antitumor effects.

Conclusions  The nonviral gene delivery system was well tolerated, and combined mIL-2 and mIL-12 gene transfer generated potent antitumor immune responses against HNSCC in our murine model. Combined nonviral IL-2 and IL-12 gene therapy may have great potential as a primary or adjuvant treatment for HNSCC in humans.

From the Department of Otolaryngology–Head and Neck Surgery (Drs Li, Shugert, Guo, and O'Malley) and The Greenebaum Cancer Center (Drs Li and O'Malley), University of Maryland School of Medicine, Baltimore; and Valentis, Inc, The Woodlands, Tex (Mr Bishop). Dr O'Malley has a sponsored research agreement with equity options in Valentis, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2001;127(11):1403-1405.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibition of NK Cell Activity through TGF-{beta}1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer
Dasgupta et al.
J. Immunol. 2005;175:5541-5550.
ABSTRACT | FULL TEXT  

p12CDK2-AP1 Gene Therapy Strategy Inhibits Tumor Growth in an In vivo Mouse Model of Head and Neck Cancer
Figueiredo et al.
Clin. Cancer Res. 2005;11:3939-3948.
ABSTRACT | FULL TEXT  

Effects of Combined Therapy With Interleukin 2 and Interleukin 12 Gene-Transfected Tumor Vaccine for Head and Neck Carcinoma
Kimura et al.
Arch Otolaryngol Head Neck Surg 2003;129:1181-1185.
ABSTRACT | FULL TEXT  

Gene Therapy for the Treatment of Oral Squamous Cell Carcinoma
Xi and Grandis
JDR 2003;82:11-16.
ABSTRACT | FULL TEXT